Sanofi collaborates with Dr. Reddy’s Labs to promote and distribute its vaccine brands in India

Under this collaboration, established vaccine brands for both paediatric and adult populations, such as Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel, and Avaxim 80U will be marketed and promoted Dr. Reddy’s Laboratories in India.

These brands collectively generated approximately Rs 426 crore ($51 million) in sales as of IQVIA MAT February 2024.

Sanofi has stated it will retain ownership, manufacturing, and importation rights for these brands in the country.

M.V. Ramana, CEO of branded markets (India and emerging markets) at DRL, expressed the company's enthusiasm for using this partnership to cater to over 1.5 billion patients by 2030.

He highlighted their plans to capitalize on their strengths in marketing and distribution to significantly enhance collaboration with healthcare professionals and facilitate broader access to Sanofi's established and trusted vaccine brands in India.

“We continue our efforts to become the partner of choice in bringing novel, innovative and trusted drugs to patients in India through strategic collaborations. The portfolio now gives Dr. Reddy’s a strong presence in the vaccine segment, propelling us to the second position among vaccines players in India," Ramana said.

The tie-up strengthens DRL’s portfolio and elevates it to second position among vaccine players in India.

“The partnership continues Dr. Reddy’s efforts to become the partner of choice in increasing access to novel, innovative as well as trusted drugs for patients in India," the company said.

“Vaccine confidence has reached its highest [level] in India in the past few years. We’re confident this partnership will further bolster our promise of saving millions of lives against vaccine-preventable diseases with improved vaccination coverage," said Preeti Futnani, general manager India for vaccines at Sanofi.